PTI - Proteostasis Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.0400
-0.0100 (-0.95%)
As of 1:12PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.0500
Open1.0600
Bid1.0200 x 2900
Ask1.0300 x 1200
Day's Range1.0246 - 1.0600
52 Week Range0.9100 - 10.3800
Volume300,236
Avg. Volume2,183,687
Market Cap53.143M
Beta (3Y Monthly)-1.82
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • How Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Could Add Value To Your Portfolio
    Simply Wall St.5 days ago

    How Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Could Add Value To Your Portfolio

    I've been keeping an eye on Proteostasis Therapeutics, Inc. (NASDAQ:PTI) because I'm attracted to its fundamentals...

  • Vertex Selects Triple Combo Regimen for Regulatory Submission
    Zacks19 days ago

    Vertex Selects Triple Combo Regimen for Regulatory Submission

    Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.

  • Proteostasis Therapeutics (PTI) Reports Q1 Loss, Tops Revenue Estimates
    Zackslast month

    Proteostasis Therapeutics (PTI) Reports Q1 Loss, Tops Revenue Estimates

    Proteostasis (PTI) delivered earnings and revenue surprises of 34.88% and 525.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Proteostasis: 1Q Earnings Snapshot

    On a per-share basis, the Boston-based company said it had a loss of 28 cents. The biopharmaceutical company posted revenue of $5 million in the period. In the final minutes of trading on Wednesday, the ...

  • Proteostasis (PTI) to Post Q1 Earnings: What's in Store?
    Zackslast month

    Proteostasis (PTI) to Post Q1 Earnings: What's in Store?

    During Proteostasis' (PTI) Q1 earnings call, investor focus will be on its update pertaining to the progress of studies, evaluating its triple combination regimes for cystic fibrosis.

  • Market Sentiment Around Loss-Making Proteostasis Therapeutics, Inc. (NASDAQ:PTI)
    Simply Wall St.2 months ago

    Market Sentiment Around Loss-Making Proteostasis Therapeutics, Inc. (NASDAQ:PTI)

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Proteostasis Therapeutics, Inc.'s (NASDAQ:PTI): Proteostasis Therapeutics, Inc., a clinical sta...

  • Analysts Estimate Proteostasis Therapeutics (PTI) to Report a Decline in Earnings: What to Look Out for
    Zacks2 months ago

    Analysts Estimate Proteostasis Therapeutics (PTI) to Report a Decline in Earnings: What to Look Out for

    Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Implied Volatility Surging for Proteostasis Therapeutics (PTI) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for Proteostasis Therapeutics (PTI) Stock Options

    Investors need to pay close attention to Proteostasis Therapeutics (PTI) stock based on the movements in the options market lately.

  • Proteostasis Plunges on Weak Data From Cystic Fibrosis Study
    Zacks3 months ago

    Proteostasis Plunges on Weak Data From Cystic Fibrosis Study

    Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations.

  • Some Proteostasis Therapeutics (NASDAQ:PTI) Shareholders Have Taken A Painful 86% Share Price Drop
    Simply Wall St.3 months ago

    Some Proteostasis Therapeutics (NASDAQ:PTI) Shareholders Have Taken A Painful 86% Share Price Drop

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! As an investor, mistakes are inevitable. But really big lossesRead More...

  • Benzinga3 months ago

    The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 25) Axsome Therapeutics Inc (NASDAQ: AXSM ) Catalyst Pharmaceuticals ...

  • Why Vertex's Grip On This Huge Sales Opportunity Now Looks Unbreakable
    Investor's Business Daily3 months ago

    Why Vertex's Grip On This Huge Sales Opportunity Now Looks Unbreakable

    A tiny biotech called Proteostasis won't be able to rival Vertex in cystic fibrosis treatment, analysts said Monday. Proteostasis' triple-medicine missed the bar set by Vertex's treatment.

  • Proteostatis stock plunges on cystic fibrosis triple combo data
    American City Business Journals3 months ago

    Proteostatis stock plunges on cystic fibrosis triple combo data

    What would otherwise be promising data led to a 60 percent stock price slide, as it falls far below both triple combination treatments being developed by the cystic fibrosis market leader, Vertex.

  • MarketWatch3 months ago

    Proteostasis Therapeutics's stock plunges to pace all decliners after results of CF treatment trial disappoint

    Shares of Proteostasis Therapeutics Inc. plunged 58% on heavy volume in morning trade Monday, enough to pace all decliners trading on major U.S. exchanges, after biopharmaceutical company announced results from a phase 1 study of its cystic fibrosis (CF) treatment. Trading volume ballooned to 7.6 million shares, compared with the full-day average of 1.2 million shares. The company said the increase in ppFEV1 at day 14 of a statistically significant 5 percentage points versus baseline was observed in the 600 milligram PTI-801 cohort. Analyst Geoffrey Porges at SVB Leerink said the results CF did not meet the efficacy of Vertex Pharmaceuticals Inc.'s medicines, as that 5% was below the 13%-14% hurdle established by Vertex. Porges believes the results of Proteostasis' trial removes the final "long-shot competitor" to Vertex's CF portfolio. Vertex shares gained 1.0% in morning trade. Proteostasis's stock has lost 66.3% over the past 12 months, while Vertex shares have rallied 13.8% and the S&P 500 has gained 7.8%.

  • Benzinga3 months ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

    Biotech stocks came under pressure last week despite two FDA approvals coming through. The FDA approved SAGE Therapeutics Inc (NASDAQ: SAGE )'s drug to treat postpartum depression and Jazz Pharmaceuticals ...

  • Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed
    Zacks3 months ago

    Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed

    Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-445 plus tezacaftor and ivacaftor meet the primary endpoint. The company delays filing for U.S. approval.

  • How Much Of Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Do Institutions Own?
    Simply Wall St.4 months ago

    How Much Of Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Do Institutions Own?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! A look at the shareholders of ProteostasisRead More...

  • Benzinga6 months ago

    The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 20) • XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech ...

  • How Many Insiders Bought Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Shares?
    Simply Wall St.6 months ago

    How Many Insiders Bought Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...

  • Waltham's Eloxx aims to reach cystic fibrosis patients that Vertex can't
    American City Business Journals6 months ago

    Waltham's Eloxx aims to reach cystic fibrosis patients that Vertex can't

    The Waltham startup is taking on the market giant Vertex Pharmaceuticals by developing an injection that targets the 10 percent of patients that Vertex and others haven't touched.

  • This Week's Top Tech Earnings and Today's Trending Stocks: PTI & NBEV
    Zacks6 months ago

    This Week's Top Tech Earnings and Today's Trending Stocks: PTI & NBEV

    Ryan McQueeney discusses concerns about slowing economic growth in China and a major court ruling affecting healthcare stocks. He also highlights trending stocks Proteostasis Therapeutics and New Age Beverages. Later, he previews earnings from Red Hat, Oracle, and Micron.

  • Biotech News: Proteostasis Therapeutics (PTI) Stock Soars on Genentech
    InvestorPlace6 months ago

    Biotech News: Proteostasis Therapeutics (PTI) Stock Soars on Genentech

    The Boston, Mass.-based company said that it has reached an exclusive license agreement to offer the rights for a Genentech product–the company is part of the Roche Group. The product in question are therapeutic small molecule modulators designed to treat some form of cystic fibrosis with an undisclosed target to be integrated from the Proteostasis network. The deal does not include the cystic fibrosis transmembrane conductance regulator (CFTR) modulators and it has no connection to PTI’s investigational medicines or any of its other ongoing research programs linked to the ailment. “We are thrilled to enter into this agreement with Genentech, an industry leader with a proven record of success in small molecule research and development,” said Meenu Chhabra, who is the President and CEO of Proteostasis Therapeutics.

  • Benzinga6 months ago

    Proteostasis Therapeutics Rallies On Genentech Licensing Agreement

    Proteostasis Therapeutics develops therapies for the treatment of cystic fibrosis, or CF, and other diseases and struck an agreement with Genentech for the rights to a potential therapeutic small molecule modulators of an undisclosed target within the Proteostasis Network. In exchange for the rights, Proteostasis will receive upfront milestone payments of more than $100 million from Genentech and tiered royalties on sales of future medicines from the license agreement. Proteostasis Therapeutics' new licensing agreement validates its network potential and could be seen as a sign that future agreements will arise, Cantor Fitzgerald's Elemer Piros said in a research report.

  • Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed
    Zacks7 months ago

    Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed

    Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-659 plus tezacaftor and ivacaftor meet the primary endpoint. Stock rises almost 5%.